| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000nam a2200000 i 4500 |
| 001 |
in00005774621 |
| 005 |
20260327190310.8 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
250329s2024 enka ob 000 0 eng d |
| 040 |
|
|
|a SFB
|b eng
|e rda
|e pn
|c SFB
|d OCLCO
|d OCLCQ
|d SFB
|
| 020 |
|
|
|a 9780443191190
|
| 020 |
|
|
|a 0443191190
|
| 020 |
|
|
|a 9780443191206
|
| 020 |
|
|
|a 0443191204
|
| 035 |
|
|
|a (OCoLC)1514681774
|
| 050 |
|
4 |
|a QR41.2
|b .M537 2024
|
| 082 |
0 |
4 |
|a 616.9101
|2 23
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Microbes at Bio/Nano Interfaces /
|c edited by Paul Ramsland, Aaron Elbourne, and Volker Gurtler.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a London :
|b Academic Press,
|c [2024]
|
| 264 |
|
4 |
|c ©2024
|
| 300 |
|
|
|a 1 online resource (302 pages).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Methods in Microbiology Series ;
|v Volume 54
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources.
|
| 588 |
|
|
|a Description based on print version record.
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
0 |
|
|a Intro -- Microbes at Bio/Nano Interfaces -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Advanced hydrogel for management of bacterial wound infections -- 1. Introduction -- 1.1. Wound healing phases -- 1.1.1. Types of wounds -- 1.1.2. Bacterial chronic wound infection -- 1.2. The challenges of antimicrobial resistance -- 1.3. Wound practice and management -- 1.4. An ideal hydrogel for clinical wound management -- 1.4.1. Classification of hydrogels -- 1.4.2. Hydrogels for wound infection application -- 1.5. Silver-impregnated antibacterial hydrogel -- 1.5.1. Delivery of silver nanoparticles using hydrogel -- 1.6. Smart hydrogels -- 1.6.1. Temperature-responsive antibacterial hydrogels -- 1.6.2. pH-responsive antibacterial hydrogels -- 1.6.3. Photothermal-responsive antibacterial hydrogels -- 1.6.4. Biochemical-responsive antibacterial hydrogels -- 1.6.5. Multi responsive hydrogel as antibacterial hydrogel -- 2. Conclusion -- Glossary -- Reference -- Chapter Two: Biofilm characterization: Imaging, analysis and considerations -- 1. Introduction -- 1.1. Biofilm formation -- 1.2. Phenotypic variations -- 1.3. Environmental effects -- 1.4. Medical relevance -- 1.5. Importance of characterization techniques -- 2. Microscopy techniques -- 2.1. Light microscopy -- 2.2. Confocal laser scanning microscopy -- 2.3. Electron microscopy -- 2.4. Scanning electron microscopy -- 2.4.1. Preparation of biofilm samples for SEM -- 2.5. Cryo-SEM -- 2.6. Transmission electron microscopy -- 2.7. Atomic force microscopy -- 3. Infrared spectroscopy -- 4. Raman spectroscopy -- 5. Microbial and molecular techniques -- 5.1. Colony-forming unit enumeration -- 5.2. Flow-based cell counting -- 5.3. Quantitative polymerase chain reaction -- 5.4. Crystal violet assays -- 6. Methods for biofilm removal for testing -- 7. Sensors -- 7.1. Optical sensors.
|
| 505 |
8 |
|
|a 7.2. Electrochemical sensors -- 7.3. Mechanical sensors -- 7.4. Lab-on-a-chip sensors -- 8. Conclusions -- References -- Chapter Three: Functional genomics methods to target the interface between schistosomes and the host immune system -- 1. Gene technology in parasitic helminths -- 2. Brief history of approaches to schistosome transgenesis -- 2.1. Schistosomiasis -- 2.2. Schistosome functional genomics -- 3. Overview of immune responses to schistosome infection -- 4. Lentiviral system for the delivery of silencing constructs -- 5. Latest advancements in schistosome transgenesis using CRISPR/Cas9 -- 5.1. Concluding remarks -- 6. Methodological considerations for the pseudotyped Lentivirus method -- References -- Chapter Four: Investigation of microbes and surface carbohydrates using atomic force microscopy -- 1. Introduction -- 1.1. Bacterial surface scanning -- 1.2. AFM imaging of proteins -- 1.3. Bacterial glycosylation -- 1.4. Using AFM to probe viruses and virus-like particles -- 1.5. Immobilising bacterial cells for AFM imaging -- 1.6. Use of immunoassays and binding assays in conjunction with AFM to investigate microorganisms and virus-like particles -- 2. Materials and methods -- 2.1. Immunofluorescence methods -- 2.2. Immunofluorescence materials -- 2.3. Direct enzyme linked-immunosorbent assay (ELISA) and enzyme linked-lectin assay (ELLA) materials -- 2.4. Atomic force microscopy methods -- 2.5. Atomic force microscopy materials -- 3. Protocols -- 3.1. Immunofluorescence and labelled lectin staining protocol -- 3.2. Direct ELISA and ELLA protocol -- 3.3. Atomic force microscopy protocol -- 4. Analysis and troubleshooting -- 4.1. Immunofluorescence -- 4.2. Direct ELISA and ELLA -- 4.3. Atomic force microscopy -- 5. Conclusions -- 6. Notes -- References -- Chapter Five: Interactions between microbial cells and titanium implant surfaces.
|
| 505 |
8 |
|
|a 1. Introduction -- 2. Antimicrobial resistance -- 3. How do infection causing microbes infiltrate a surface? -- 3.1. Bacterial and fungal attachment and biofilm formation on surfaces -- 3.2. Mechanism and stages of formation -- 3.2.1. Stages of cell adhesion to surfaces -- 3.2.2. Two stages of cell adhesion -- 3.3. Methods of surface attachment -- 3.3.1. Cellular appendages -- 3.3.2. Chemical methods of attachment -- 3.3.3. Cell-to-cell communication -- 3.3.4. Quorum sensing in gram-negative bacteria -- 3.3.5. Quorum sensing in gram-positive bacteria -- 3.3.6. Quorum sensing in fungal cells -- 3.3.7. Adhesion molecules in fungal cells -- 4. Impacts of surface properties on cellular adhesion -- 4.1. Influence of surface wettability -- 4.2. Influence of surface roughness and topography -- 4.3. Influence of surface charge -- 5. Common implant surfaces -- 6. Properties of titanium implants -- 6.1. Osseointegration-Implants interfacing with the body -- 7. Antimicrobial surfaces -- 7.1. Bactericidal or antifouling surface? -- 8. Titanium surface modification to combat adhesion and proliferation -- 8.1. Nanoparticles -- 8.1.1. Silver -- 8.1.2. Copper -- 8.1.3. Zinc oxide -- 8.1.4. Selenium -- 8.1.5. Titanium dioxide -- 8.2. Physical modification of titanium surfaces -- 8.2.1. Roughness -- 8.2.2. Nanostructures -- 8.3. Coatings -- 8.3.1. Antibiotic drug coatings -- 9. Additive manufacturing of titanium implant materials -- 10. Conclusion -- References -- Chapter Six: Targeting bacterial polysaccharides with antibodies and vaccines -- 1. Introduction to bacterial polysaccharides -- 1.1. Bacterial polysaccharides: Structure and function -- 1.1.1. Definition of bacterial polysaccharides -- 1.1.2. Overview of polysaccharide structures -- 1.1.3. Importance of bacterial polysaccharides in pathogenesis -- 1.2. Antibodies and vaccines: An overview.
|
| 505 |
8 |
|
|a 1.2.1. Introduction to antibodies and their role in the immune system -- 1.2.2. Overview of vaccines and their purpose -- 1.2.3. Importance of targeting bacterial polysaccharides with antibodies and vaccines -- 2. Antibodies as tools for targeting bacterial polysaccharides -- 2.1. Antibodies and their specificity -- 2.1.1. Antibody structure and function -- 2.1.2. Antibody-antigen interactions -- 2.1.3. Specificity of antibodies for bacterial polysaccharides -- 2.2. Mechanisms of antibody-mediated bacterial clearance -- 2.3. Monoclonal antibodies and their applications -- 2.3.1. Introduction to monoclonal antibodies -- 2.3.2. Production and characterization of monoclonal antibodies -- 2.3.3. Therapeutic and diagnostic applications of monoclonal antibodies targeting bacterial polysaccharides -- 3. Vaccines targeting bacterial polysaccharides -- 3.1. Polysaccharide vaccines -- 3.1.1. Introduction to polysaccharide vaccines -- 3.1.2. Examples of polysaccharide vaccines and their targets -- 3.1.3. Mechanisms of protection provided by polysaccharide vaccines -- 3.2. Conjugate vaccines -- 3.2.1. Rationale behind conjugate vaccines -- 3.2.2. Conjugation methods for bacterial polysaccharides -- 3.2.3. Clinical success and impact of conjugate vaccines -- 3.3. Challenges and advances in polysaccharide vaccinology -- 3.3.1. Immunological challenges of targeting bacterial polysaccharides -- 3.3.2. Novel approaches for polysaccharide vaccine design -- 3.3.3. Adjuvants and their role in enhancing vaccine efficacy -- 4. Case studies and success stories -- 4.1. Haemophilus influenzae type b (Hib) -- 4.1.1. Background and clinical significance -- 4.1.2. Development and impact of Hib conjugate vaccines -- 4.2. Streptococcus pneumoniae -- 4.2.1. Overview of pneumococcal disease -- 4.2.2. Pneumococcal polysaccharide and conjugate vaccines -- 4.3. Neisseria meningitidis.
|
| 505 |
8 |
|
|a 4.3.1. Meningococcal disease and its impact -- 4.3.2. Meningococcal polysaccharide and conjugate vaccines -- 5. Future directions and conclusion -- 5.1. Advances in bacterial polysaccharide research -- 5.1.1. Glycoengineering and synthetic glycobiology -- 5.1.2. Structural and functional characterization techniques -- 5.1.3. Novel targets and strategies for antibody and vaccine development -- 5.2. Implications for public health -- 5.2.1. The role of bacterial polysaccharide-targeting antibodies and vaccines in disease prevention -- 5.2.2. Challenges and opportunities in global vaccine implementation -- 6. PNAG polysaccharide: Structure, genetics, immunity, and clinical prospects -- 6.1. General structure of PNAG -- 6.2. Genetics and biosynthesis of PNAG -- 6.2.1. The ica and pga loci -- 6.2.2. The hms locus of Y. pestis and eps locus of Bacillus subtilis -- 6.3. Detection of PNAG expression by a broad range of microbial pathogens -- 6.4. Functional properties of PNAG -- 6.5. Naturally-occurring antibodies to PNAG -- 6.6. Discovery of the means to successfully induce functional immunity to PNAG: PNAG vs dPNAG and production of synthetic ... -- 6.7. In vitro correlates of PNAG-mediated immunity -- 6.7.1. ELISA antibody titers -- 6.7.2. Complement-mediated opsonic and bactericidal killing -- 6.7.3. Complement deposition assays -- 6.8. Development of human monoclonal antibody F598 against PNAG -- 6.9. Path to clinical testing -- 6.9.1. Phase 1 clinical trial of monoclonal antibody F598 -- 6.9.2. Phase 1 clinical trial of vaccine AV0328 -- 7. Conclusion -- References -- Chapter Seven: Using next generation sequencing to study host-pathogen interactions -- 1. Introduction -- 2. Methods -- 2.1. Considerations for sampling and sample storage -- 2.2. DNA extraction -- 2.3. Protocol: Bead-beating of samples -- 2.4. PCR for sequencing.
|
| 520 |
|
|
|a Advances in Virus Research serial highlights new advances in the field with this new volume presenting interesting chapters.Each chapter is written by an international board of authors.- Provides the authority and expertise of leading contributors from an international board of authors- Presents the latest release in Advances in Virus Research.
|
| 650 |
|
0 |
|a Microbiology.
|
| 650 |
|
2 |
|a Microbiology
|
| 650 |
|
6 |
|a Microbiologie.
|
| 650 |
|
7 |
|a microbiology.
|2 aat
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Ramsland, Paul,
|e editor.
|
| 700 |
1 |
|
|a Elbourne, Aaron,
|e editor.
|
| 700 |
1 |
|
|a Gurtler, Volker,
|e editor.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 830 |
|
0 |
|a Methods in microbiology ;
|v Volume 54.
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/bookseries/05809517/54
|z Connect to the full text of this electronic book
|t 0
|
| 936 |
|
|
|a BATCHLOAD
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 32e2f23a-659e-4e30-9954-22ae564c1fc9
|s bda65ed8-0eec-4345-81fc-1ec6561f6032
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e QR41.2 .M537 2024
|h Library of Congress classification
|
| 998 |
f |
f |
|a QR41.2 .M537 2024
|t 0
|l Available Online
|